Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 1 7Phase 3 2Phase 1/2 2

Status

Unknown 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Carcinoma, Hepatocellular 26Neoplasms 7Liver Neoplasms 7Leukemia, Myeloid, Acute 6Carcinoma, Renal Cell 5Breast Neoplasms 5Recurrence 3Leukemia 3Kidney Neoplasms 3Glioblastoma 3Carcinoma, Non-Small-Cell Lung 3Brain Neoplasms 3Sarcoma 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Multiple Myeloma 2Melanoma 2Leukemia, Myelomonocytic, Chronic 2Gliosarcoma 2Colorectal Neoplasms 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Stomach Neoplasms 1Sezary Syndrome 1Rectal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Squamous Cell 1Neoplasms, Plasma Cell 1

Interventions

pembrolizumab 74Nivolumab 53Ipilimumab 42Cyclophosphamide 32Interleukin-2 24aldesleukin 23Temozolomide 17fludarabine 16Biopsy 11trametinib 10fludarabine phosphate 10dabrafenib 10spartalizumab 8Paclitaxel 8Dacarbazine 8sargramostim 7cemiplimab 7binimetinib 7Cisplatin 7Bevacizumab 7poly ICLC 6lenvatinib 6epacadostat 6Radiotherapy 6Granulocyte-Macrophage Colony-Stimulating Factor 6montanide ISA 51 5encorafenib 5atezolizumab 5Vemurafenib 5Specimen Handling 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Melanoma × Sorafenib × Clear all
NCT00538005 2014-01-10

Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma

National Cancer Institute (NCI)

Phase 1/2 Unknown
54 enrolled
Dermatologic

Melanoma

NCT00811759 2010-10-07

Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma

National Cancer Institute (NCI)

Phase 1/2 Unknown
58 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡